SEC Comment Letter 0000000000-24-003036 to Spero Therapeutics, Inc. (SPRO) (CIK 0001701108) (SPRO)
Spero Therapeutics, Inc. (SPRO) (CIK 0001701108)
Date: March 20, 2024 · CIK: 0001701108 · Accession: 0000000000-24-003036
AI Filing Summary & Sentiment
File numbers found in text: 333-277998
Letter
United States securities and exchange commission logo March 20, 2024 Satyavrat Shukla President and Chief Executive Officer Spero Therapeutics, Inc. 675 Massachusetts Avenue, 14th Floor Cambridge, MA 02139 Re:Spero Therapeutics, Inc. Registration Statement on Form S-3 Filed March 15, 2024 File No. 333-277998 Dear Satyavrat Shukla: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Cindy Polynice at 202-551-8707 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Matthew Gardella, Esq.
Show Raw Text
United States securities and exchange commission logo
March 20, 2024
Satyavrat Shukla
President and Chief Executive Officer
Spero Therapeutics, Inc.
675 Massachusetts Avenue, 14th Floor
Cambridge, MA 02139
Re:Spero Therapeutics, Inc.
Registration Statement on Form S-3
Filed March 15, 2024
File No. 333-277998
Dear Satyavrat Shukla:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Cindy Polynice at 202-551-8707 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Matthew Gardella, Esq.